Published in J Hepatol on July 30, 2014
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) (DRIVE-C) | NCT03537196
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis (2015) 1.78
The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.51
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (2015) 1.48
Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med (2016) 1.44
Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. PLoS Pathog (2015) 1.44
Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis (2016) 1.44
Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey. PLoS One (2016) 1.41
World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology (2015) 1.38
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Epidemiology of hepatitis C virus in Iran. World J Gastroenterol (2015) 1.01
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol (2016) 0.95
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med (2016) 0.94
Access to hepatitis C medicines. Bull World Health Organ (2015) 0.93
New approaches in the treatment of hepatitis C. World J Gastroenterol (2016) 0.90
Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89
Genome editing and the next generation of antiviral therapy. Hum Genet (2016) 0.88
Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One (2015) 0.87
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon (2016) 0.86
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol (2016) 0.85
Update on hepatitis B and C virus diagnosis. World J Virol (2015) 0.85
A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med (2015) 0.85
The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One (2015) 0.85
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis (2016) 0.84
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J (2015) 0.84
Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol (2016) 0.84
Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon (2016) 0.84
Immunomodulatory effects of transforming growth factor-β in the liver. Hepatobiliary Surg Nutr (2014) 0.83
Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir. Antimicrob Agents Chemother (2015) 0.83
Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS One (2015) 0.83
Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS One (2016) 0.82
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother (2016) 0.82
HIV and HCV Medications in End-Stage Renal Disease. Semin Dial (2015) 0.82
Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. World J Gastroenterol (2015) 0.80
The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol (2015) 0.80
Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections. Front Microbiol (2014) 0.80
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open (2015) 0.80
A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients. J Hum Genet (2015) 0.80
Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon (2016) 0.80
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World J Gastroenterol (2016) 0.79
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology (2017) 0.79
The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int (2016) 0.79
Protein interactions during the flavivirus and hepacivirus life cycle. Mol Cell Proteomics (2017) 0.79
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf (2016) 0.79
Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol (2016) 0.79
Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol (2015) 0.79
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. ACS Chem Biol (2016) 0.79
HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clin Exp Gastroenterol (2016) 0.79
New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr (2016) 0.79
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol (2016) 0.79
Highly heterogeneous mutation rates in the hepatitis C virus genome. Nat Microbiol (2016) 0.79
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother (2017) 0.79
Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses. J Virol (2015) 0.79
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol (2016) 0.78
What's new in hepatitis C virus infections in children? World J Gastroenterol (2015) 0.78
Thyroid Peroxidase Antibodies in Non-Interferon Treated Hepatitis C Patients in Pakistan. Biomed Res Int (2015) 0.78
Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol (2015) 0.78
Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol (2015) 0.78
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev (2016) 0.78
Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand. World J Gastroenterol (2015) 0.78
Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics. PLoS One (2015) 0.78
Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol (2016) 0.77
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Braz J Med Biol Res (2016) 0.77
Diagnosis of viral hepatitis. Curr Opin HIV AIDS (2017) 0.77
Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center. J Clin Exp Hepatol (2015) 0.77
Heterogeneous Ribonucleoprotein K (hnRNP K) Binds miR-122, a Mature Liver-Specific MicroRNA Required for Hepatitis C Virus Replication. Mol Cell Proteomics (2015) 0.77
Hepatitis C genotype 4: The past, present, and future. World J Hepatol (2015) 0.77
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Requirement for chloride channel function during the hepatitis C virus life cycle. J Virol (2015) 0.77
Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. J Int AIDS Soc (2016) 0.77
The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon (2016) 0.77
Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Hubei, Central China. PLoS One (2015) 0.77
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infect Dis (2016) 0.77
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. Dig Dis Sci (2016) 0.77
Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. J Am Chem Soc (2016) 0.76
Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. J Adv Res (2016) 0.76
In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease. Sci Rep (2016) 0.76
Diverse origins of hepatitis C virus in HIV co-infected men who have sex with men in Hong Kong. Virol J (2015) 0.76
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res (2016) 0.76
Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis. BMC Infect Dis (2016) 0.76
HCV core protein binds to gC1qR to induce A20 expression and inhibit cytokine production through MAPKs and NF-κB signaling pathways. Oncotarget (2016) 0.76
Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum. J Clin Microbiol (2016) 0.75
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. Int J Mol Sci (2016) 0.75
Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature. Am J Case Rep (2016) 0.75
Viral hepatitis: Indian scenario. Med J Armed Forces India (2016) 0.75
The full-length genome sequences of nine HCV genotype 4 variants representing a new subtype 4s and eight unclassified lineages. Virology (2015) 0.75
Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus (2016) 0.75
Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis (2016) 0.75
A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. PLoS One (2016) 0.75
Duplex High-Resolution Melting Assay for the Simultaneous Genotyping of IL28B rs12979860 and PNPLA3 rs738409 Polymorphisms in Chronic Hepatitis C Patients. Int J Mol Sci (2015) 0.75
Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. PLoS One (2016) 0.75
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol (2016) 0.75
Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study. BMC Infect Dis (2015) 0.75
Comparison of structural architecture of HCV NS3 genotype 1 versus Pakistani genotype 3a. Biomed Res Int (2014) 0.75